Compare OPRX & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | RPID |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.1M | 102.6M |
| IPO Year | 2008 | 2021 |
| Metric | OPRX | RPID |
|---|---|---|
| Price | $6.38 | $2.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $16.67 | $8.00 |
| AVG Volume (30 Days) | ★ 301.7K | 240.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | 2.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,429,000.00 | $33,587,000.00 |
| Revenue This Year | $3.88 | $19.12 |
| Revenue Next Year | $8.34 | $18.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 18.78 | ★ 19.74 |
| 52 Week Low | $4.54 | $1.66 |
| 52 Week High | $22.25 | $4.94 |
| Indicator | OPRX | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 51.88 |
| Support Level | $6.03 | $1.98 |
| Resistance Level | $6.93 | $2.17 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 48.47 | 50.00 |
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.